Dublin-headquartered healthcare technology company Lanas has strengthened its senior leadership team with the appointment of an experienced mergers and acquisitions executive to drive its corporate development strategy across global markets.

According to a report by The Malaysian Reserve, Rob Hutcheson has been named Chief Corporate Development Officer at Lanas, bringing more than 20 years of experience in mergers and acquisitions, corporate development, and growth strategy, including more than 15 years focused specifically on healthcare technology at PwC and Civica. Hutcheson is based in Brisbane and will work closely with founders, management teams, and investors to identify complementary healthcare technologies that strengthen Lanas' capabilities across the UK, Ireland, Australia, and New Zealand.

Lanas builds, acquires, and scales healthcare technology products used across primary care, community care, pharmacy, specialist care, and care platforms. Launched in November 2025 and backed by global private equity firm TA Associates, the company operates with a committed M&A funding package of €100 million and currently offers more than 20 products and services serving clinicians across two hemispheres.

Howard Beggs, Founder and Chief Executive Officer of Lanas, said: "Rob brings deep healthcare technology and M&A experience, and he'll play an important role as we continue to strengthen our offering and create greater value for customers."

Hutcheson said he was attracted by the strength of Lanas' existing business and the opportunity to shape its future growth: "There's a significant opportunity to build on that through disciplined strategic acquisitions. I'm looking forward to working with founders, management teams and investors to identify technologies that strengthen our capabilities, expand our offering and help solve real healthcare challenges."

The appointment reflects Lanas' stated long-term strategy of expanding through both product innovation and targeted acquisitions, with a particular focus on advancing the electronic health record market through operational excellence. With customers and operations spanning the UK, Ireland, Australia, and New Zealand, the company is positioning itself as a significant consolidator in the global healthcare technology sector.

For private healthcare operators and technology decision-makers, the appointment of a dedicated corporate development leader signals an accelerating acquisition pipeline from a well-capitalised platform with a clear remit to expand its footprint across multiple healthcare settings and geographies.